Lupus & antiphospholipid syndrome
Beyond paraneoplastic neurological syndromes: Anti-neuronal antibodies in neuropsychiatric systemic lupus erythematosus
Authors' conclusion
Anti-neuronal antibodies were more likely to be positive in active neuropsychiatric lupus patients, and these antibodies which are commonly used to diagnose paraneoplastic syndromes may have a potential role in the diagnosis of NPSLE.
Study context
- Population
- NPSLE patients (1999 American College of Rheumatology (ACR) nomenclature and case definitions), single centre, 2019 to 2022
- Participants
- 65 patients
- Exposure
- Active vs inactive NPSLE
- Active NPSLEn = 23
- Outcome
- Frequency of anti-neuronal antibodies (semi-quantitative line immunoassay panel)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Anti-neuronal antibody positivity
- Anti-neuronal antibodies positive
- 13/65 (20%)
- Anti-GAD 65 (highest frequency)
- 6.2%
- Anti-CV2
- 3.1%
- Anti-SOX1
- 3.1%
- Anti-amphiphysin
- 3.1%
- Anti-recoverin
- 1.5%
- Anti-Yo
- 1.5%
- Anti-Zic
- 1.5%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Anti-neuronal antibody positivity, activevs inactive disease | 10 (2.38–42) | P < 0.001 | |
| 0.050.21520Odds ratio (log scale) |
Association with specific NPSLE features
- The panel of anti-neuronal antibodies did not show any specific association with NPSLE features
Original publication
Beyond paraneoplastic neurological syndromes: Anti-neuronal antibodies in neuropsychiatric systemic lupus erythematosus. Lupus. Published 21 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →